| Companies sponsors |
Pfizer (marstacimab) |
| Others |
Department of Health and Social Care |
| |
NHS England |
| Patient carer groups |
Gene People |
| |
The Haemophilia Society |
| Professional groups |
Royal College of Physicians |
| Associated public health groups |
None |
| Comparator companies |
Bio Products Laboratory (factor IX, factor VIII) (confidentiality agreement not signed, not participating) |
| |
CSL Behring (etranacogene dezaparvovec, factor IX, factor VIII) (confidentiality agreement signed, participating) |
| |
Grifols UK (factor IX, factor VIII) (confidentiality agreement not signed, not participating) |
| |
Novo Nordisk Ltd (factor VIII, eptacog alfa, nonacog beta pegol, turoctocog alfa pegol) (confidentiality agreement signed, participating) |
| |
Octapharma (factor VIII, simoctocog alfa) (confidentiality agreement not signed, not participating) |
| |
Pfizer (fidanacogene elaparvovec, moroctocog alfa, nonacog alfa) (confidentiality agreement not signed, not participating) |
| |
Roche products (emicizumab) (confidentiality agreement signed, participating) |
| |
Swedish Orphan Biovitrum (efanesoctocog alfa, efmoroctocog alfa, eftrenonacog alfa) (confidentiality agreement signed, participating) |
| |
Takeda (factor IX, factor VIII, octocog alfa, rurioctocog alfa pegol, susoctocog alfa) (confidentiality agreement not signed, not participating) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health – Northern Ireland |
| |
Haemophilia Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
Scottish Medicines Consortium |
| |
Welsh Government |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
None |